{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T12:22:15Z","timestamp":1792671735103,"version":"4.5.0"},"reference-count":32,"publisher":"Becaris Publishing Limited","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Comp. Eff. Res."],"published-print":{"date-parts":[[2026,2]]},"abstract":"<jats:p>\n                    <jats:bold>Aim:<\/jats:bold>\n                    There is limited real-world evidence about prostate-specific antigen (PSA) response to androgen receptor pathway inhibitor treatment in Black patients with metastatic castration-sensitive prostate cancer (mCSPC). This study compared PSA90 (\u226590% reduction from baseline PSA level) between apalutamide and enzalutamide among Black patients with mCSPC.\n                    <jats:bold>Materials &amp; methods:<\/jats:bold>\n                    Electronic medical record data (Precision Point Specialty Analytics) were linked to claims data (Komodo Research Database) and used to select cohorts of Black patients with mCSPC treated with either apalutamide or enzalutamide. Inverse probability of treatment weighting was used to balance treatment cohorts. PSA90 response was assessed using weighted Kaplan\u2013Meier curves and hazard ratios with 95% CIs.\n                    <jats:bold>Results:<\/jats:bold>\n                    The study included 451 patients (apalutamide: 230, enzalutamide: 221) with balanced baseline characteristics after inverse probability of treatment weighting. Patients treated with apalutamide had a 42% higher rate of PSA90 response within 6\u00a0months post-index compared with those treated with enzalutamide (hazard ratio: 1.42, 95% CI: 1.06, 1.91; p\u00a0=\u00a00.020). Median time to first PSA90 response was shorter among patients treated with apalutamide (3.3\u00a0months) compared with enzalutamide (5.5\u00a0months).\n                    <jats:bold>Conclusion:<\/jats:bold>\n                    In Black patients with mCSPC, apalutamide led to faster and significantly deeper PSA responses than enzalutamide, suggesting potential clinical advantages in optimizing early treatment response in this population. Future research should assess PSA90 as a prognostic indicator of overall survival among Black patients.\n                  <\/jats:p>","DOI":"10.57264\/cer-2025-0161","type":"journal-article","created":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T09:32:41Z","timestamp":1768555961000},"source":"Crossref","is-referenced-by-count":2,"title":["Comparison of deep prostate-specific antigen response in Black patients with metastatic castration-sensitive prostate cancer initiated on apalutamide or enzalutamide"],"prefix":"10.57264","volume":"15","author":[{"given":"Benjamin H","family":"Lowentritt","sequence":"first","affiliation":[{"name":"Chesapeake Urology, Towson, MD 21204, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabree","family":"Burbage","sequence":"additional","affiliation":[{"name":"Johnson &amp; Johnson, Horsham, PA 19044, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ibrahim","family":"Khilfeh","sequence":"additional","affiliation":[{"name":"Johnson &amp; Johnson, Horsham, PA 19044, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominic","family":"Pilon","sequence":"additional","affiliation":[{"name":"Analysis Group, Inc., Montr\u00e9al, QC H3B 0G7, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shawn","family":"Du","sequence":"additional","affiliation":[{"name":"Johnson &amp; Johnson, Horsham, PA 19044, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmine","family":"Rossi","sequence":"additional","affiliation":[{"name":"Analysis Group, Inc., Montr\u00e9al, QC H3B 0G7, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederic","family":"Kinkead","sequence":"additional","affiliation":[{"name":"Analysis Group, Inc., Montr\u00e9al, QC H3B 0G7, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lilian","family":"Diaz","sequence":"additional","affiliation":[{"name":"Analysis Group, Inc., Montr\u00e9al, QC H3B 0G7, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gordon","family":"Brown","sequence":"additional","affiliation":[{"name":"New Jersey Urology, Cherry Hill, NJ 08003, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"36897","reference":[{"issue":"1","key":"e_1_3_9_3_2","first-page":"10","article-title":"Cancer statistics, 2025","volume":"75","author":"Siegel RL","year":"2025","unstructured":"Siegel RL, Kratzer TB, Giaquinto AN, Sung H, Jemal A. Cancer statistics, 2025. CA Cancer J. Clin. 75(1), 10\u201345 (2025).","journal-title":"CA Cancer J. Clin."},{"issue":"21","key":"e_1_3_9_4_2","doi-asserted-by":"crossref","first-page":"3787","DOI":"10.1002\/cncr.34433","article-title":"Racial disparities in Black men with prostate cancer: a literature review","volume":"128","author":"Lillard JW","year":"2022","unstructured":"Lillard JW Jr, Moses KA, Mahal BA, George DJ. Racial disparities in Black men with prostate cancer: a literature review. Cancer 128(21), 3787\u20133795 (2022).","journal-title":"Cancer"},{"issue":"5","key":"e_1_3_9_5_2","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1158\/1055-9965.EPI-22-1038","article-title":"Estimating the number of men living with metastatic prostate cancer in the United States","volume":"32","author":"Devasia TP","year":"2023","unstructured":"Devasia TP, Mariotto AB, Nyame YA, Etzioni R. Estimating the number of men living with metastatic prostate cancer in the United States. Cancer Epidemiol. Biomarkers Prev. 32(5), 659\u2013665 (2023).","journal-title":"Cancer Epidemiol. Biomarkers Prev."},{"key":"e_1_3_9_6_2","unstructured":"National Cancer Institute Surveillance Epidemiology and End Results Progam. Cancer Stat Facts: prostate cancer 2025. (Accessed: 29 July 2025). Available from: https:\/\/seer.cancer.gov\/statfacts\/html\/prost.html"},{"issue":"1","key":"e_1_3_9_7_2","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1200\/OP.21.00206","article-title":"Recent advances in the management of metastatic prostate cancer","volume":"18","author":"Sayegh N","year":"2022","unstructured":"Sayegh N, Swami U, Agarwal N. Recent advances in the management of metastatic prostate cancer. JCO Oncol. Pract. 18(1), 45\u201355 (2022).","journal-title":"JCO Oncol. Pract."},{"key":"e_1_3_9_8_2","unstructured":"FDA approves apalutamide for metastatic castration-sensitive prostate cancer. (2019). Available from: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-apalutamide-metastatic-castration-sensitive-prostate-cancer"},{"key":"e_1_3_9_9_2","unstructured":"FDA approves enzalutamide for metastatic castration-sensitive prostate cancer. (2019). Available from: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-enzalutamide-metastatic-castration-sensitive-prostate-cancer"},{"issue":"1","key":"e_1_3_9_10_2","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1056\/NEJMoa1903307","article-title":"Apalutamide for metastatic, castration-sensitive prostate cancer","volume":"381","author":"Chi KN","year":"2019","unstructured":"Chi KN, Agarwal N, Bjartell A Apalutamide for metastatic, castration-sensitive prostate cancer. N. Engl. J. Med. 381(1), 13\u201324 (2019).","journal-title":"N. Engl. J. Med."},{"issue":"32","key":"e_1_3_9_11_2","doi-asserted-by":"crossref","first-page":"2974","DOI":"10.1200\/JCO.19.00799","article-title":"ARCHES: a randomized, Phase III study of androgen deprivation therapy with enzalutamide or placebo in men with metastatic hormone-sensitive prostate cancer","volume":"37","author":"Armstrong AJ","year":"2019","unstructured":"Armstrong AJ, Szmulewitz RZ, Petrylak DP ARCHES: a randomized, Phase III study of androgen deprivation therapy with enzalutamide or placebo in men with metastatic hormone-sensitive prostate cancer. J. Clin. Oncol. 37(32), 2974\u20132986 (2019).","journal-title":"J. Clin. Oncol."},{"issue":"5","key":"e_1_3_9_12_2","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.annonc.2023.02.009","article-title":"Deep, rapid, and durable prostate-specific antigen decline with apalutamide plus androgen deprivation therapy is associated with longer survival and improved clinical outcomes in TITAN patients with metastatic castration-sensitive prostate cancer","volume":"34","author":"Chowdhury S","year":"2023","unstructured":"Chowdhury S, Bjartell A, Agarwal N Deep, rapid, and durable prostate-specific antigen decline with apalutamide plus androgen deprivation therapy is associated with longer survival and improved clinical outcomes in TITAN patients with metastatic castration-sensitive prostate cancer. Ann. Oncol. 34(5), 477\u2013485 (2023).","journal-title":"Ann. Oncol."},{"issue":"4","key":"e_1_3_9_13_2","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/j.eururo.2019.11.021","article-title":"Correlation of prostate-specific antigen kinetics with overall survival and radiological progression-free survival in metastatic castration-sensitive prostate cancer treated with abiraterone acetate plus prednisone or placebos added to androgen deprivation therapy: post hoc analysis of Phase III LATITUDE study","volume":"77","author":"Matsubara N","year":"2020","unstructured":"Matsubara N, Chi KN, \u00d6zg\u00fcro\u011flu M Correlation of prostate-specific antigen kinetics with overall survival and radiological progression-free survival in metastatic castration-sensitive prostate cancer treated with abiraterone acetate plus prednisone or placebos added to androgen deprivation therapy: post hoc analysis of Phase III LATITUDE study. Eur. Urol. 77(4), 494\u2013500 (2020).","journal-title":"Eur. Urol."},{"issue":"2","key":"e_1_3_9_14_2","doi-asserted-by":"crossref","first-page":"41","DOI":"10.36469\/jheor.2025.141170","article-title":"Prostate-specific antigen reduction after androgen receptor pathway inhibitor initiation: real-world comparison of disease progression among patients with metastatic castration-sensitive prostate cancer","volume":"12","author":"Du S","year":"2025","unstructured":"Du S, Rossi C, Khilfeh I Prostate-specific antigen reduction after androgen receptor pathway inhibitor initiation: real-world comparison of disease progression among patients with metastatic castration-sensitive prostate cancer. J. Health Econ. Outcomes Res. 12(2), 41\u201349 (2025).","journal-title":"J. Health Econ. Outcomes Res."},{"issue":"5","key":"e_1_3_9_15_2","doi-asserted-by":"crossref","first-page":"253.e1","DOI":"10.1016\/j.urolonc.2023.03.003","article-title":"Attainment of early, deep prostate-specific antigen response in metastatic castration-sensitive prostate cancer: a comparison of patients initiated on apalutamide or enzalutamide","volume":"41","author":"Lowentritt B","year":"2023","unstructured":"Lowentritt B, Pilon D, Khilfeh I Attainment of early, deep prostate-specific antigen response in metastatic castration-sensitive prostate cancer: a comparison of patients initiated on apalutamide or enzalutamide. Urol. Oncol. 41(5), 253.e1\u2013253.e9 (2023).","journal-title":"Urol. Oncol."},{"issue":"5","key":"e_1_3_9_16_2","doi-asserted-by":"crossref","first-page":"252.e19","DOI":"10.1016\/j.urolonc.2023.03.013","article-title":"Comparison of prostate-specific antigen response in patients with metastatic castration-sensitive prostate cancer initiated on apalutamide or abiraterone acetate: a retrospective cohort study","volume":"41","author":"Lowentritt B","year":"2023","unstructured":"Lowentritt B, Pilon D, Waters D Comparison of prostate-specific antigen response in patients with metastatic castration-sensitive prostate cancer initiated on apalutamide or abiraterone acetate: a retrospective cohort study. Urol. Oncol. 41(5), 252.e19\u2013252.e27 (2023).","journal-title":"Urol. Oncol."},{"issue":"32","key":"e_1_3_9_17_2","doi-asserted-by":"crossref","first-page":"3595","DOI":"10.2217\/fon-2022-0791","article-title":"Early prostate-specific antigen response among Black and non-Black patients with advanced prostate cancer treated with apalutamide","volume":"18","author":"Bivins VM","year":"2022","unstructured":"Bivins VM, Durkin M, Khilfeh I Early prostate-specific antigen response among Black and non-Black patients with advanced prostate cancer treated with apalutamide. Future Oncol. 18(32), 3595\u20133607 (2022).","journal-title":"Future Oncol."},{"issue":"7","key":"e_1_3_9_18_2","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1001\/jamaoncol.2019.0826","article-title":"Association of Black race with prostate cancer\u2013specific and other-cause mortality","volume":"5","author":"Dess RT","year":"2019","unstructured":"Dess RT, Hartman HE, Mahal BA Association of Black race with prostate cancer\u2013specific and other-cause mortality. JAMA Oncol. 5(7), 975\u2013983 (2019).","journal-title":"JAMA Oncol."},{"issue":"4","key":"e_1_3_9_19_2","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1080\/03007995.2021.1879753","article-title":"Identification of patients with metastatic castration-sensitive or metastatic castration-resistant prostate cancer using administrative health claims and laboratory data","volume":"37","author":"Freedland SJ","year":"2021","unstructured":"Freedland SJ, Ke X, Lafeuille MH Identification of patients with metastatic castration-sensitive or metastatic castration-resistant prostate cancer using administrative health claims and laboratory data. Curr. Med. Res. Opin. 37(4), 609\u2013622 (2021).","journal-title":"Curr. Med. Res. Opin."},{"key":"e_1_3_9_20_2","volume-title":"The Hajek Estimator revisited. Proceedings of the Section on Survey Methods Research","author":"Dorfman AH","year":"1997","unstructured":"Dorfman AH, Valliant R. (Eds). The Hajek Estimator revisited. Proceedings of the Section on Survey Methods Research. American Statistical Association, VA, USA (1997)."},{"issue":"6","key":"e_1_3_9_21_2","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1080\/03610910902859574","article-title":"Using the standardized difference to compare the prevalence of a binary variable between two groups in observational research","volume":"38","author":"Austin PC","year":"2009","unstructured":"Austin PC. Using the standardized difference to compare the prevalence of a binary variable between two groups in observational research. Commun. Stat. Simul. Comput. 38(6), 1228\u20131234 (2009).","journal-title":"Commun. Stat. Simul. Comput."},{"issue":"2","key":"e_1_3_9_22_2","first-page":"e29","article-title":"Real-world comparison of deep prostate-specific antigen response in patients with metastatic castration-sensitive prostate cancer treated with apalutamide or enzalutamide","volume":"23","author":"Lowentritt B","year":"2024","unstructured":"Lowentritt B, Khilfeh I, Pilon D Real-world comparison of deep prostate-specific antigen response in patients with metastatic castration-sensitive prostate cancer treated with apalutamide or enzalutamide. Rev. Urol. 23(2), e29\u2013e40 (2024).","journal-title":"Rev. Urol."},{"issue":"2","key":"e_1_3_9_23_2","first-page":"92","article-title":"Comparison of second-generation antiandrogens for the treatment of prostate cancer","volume":"12","author":"Park SJ","year":"2022","unstructured":"Park SJ, Yoder B, Li T. Comparison of second-generation antiandrogens for the treatment of prostate cancer. J. Hematol. Oncol. Pharm. 12(2), 92\u201398 (2022).","journal-title":"J. Hematol. Oncol. Pharm."},{"issue":"2","key":"e_1_3_9_24_2","doi-asserted-by":"crossref","first-page":"41","DOI":"10.36469\/jheor.2024.121233","article-title":"Real-world clinical outcomes and treatment patterns among Black and non-Black patients with prostate cancer initiated on apalutamide in a urology setting","volume":"11","author":"Lowentritt BH","year":"2024","unstructured":"Lowentritt BH, Rossi C, Muser E Real-world clinical outcomes and treatment patterns among Black and non-Black patients with prostate cancer initiated on apalutamide in a urology setting. J. Health Econ. Outcomes Res. 11(2), 41\u201348 (2024).","journal-title":"J. Health Econ. Outcomes Res."},{"key":"e_1_3_9_25_2","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1200\/JCO.2021.39.6_suppl.94","article-title":"Overall survival (OS) and metastasis-free survival (MFS) by depth of prostate-specific antigen (PSA) decline in the Phase III PROSPER trial of men with nonmetastatic castration-resistant prostate cancer (nmCRPC) treated with enzalutamide (ENZA)","volume":"39","author":"Hussain MH","year":"2021","unstructured":"Hussain MH, Sternberg CN, Efstathiou E Overall survival (OS) and metastasis-free survival (MFS) by depth of prostate-specific antigen (PSA) decline in the Phase III PROSPER trial of men with nonmetastatic castration-resistant prostate cancer (nmCRPC) treated with enzalutamide (ENZA). J. Clin. Oncol. 39, 94 (2021).","journal-title":"J. Clin. Oncol."},{"key":"e_1_3_9_26_2","doi-asserted-by":"crossref","first-page":"5078","DOI":"10.1200\/JCO.2022.40.16_suppl.5078","article-title":"Association of prostate-specific antigen (PSA) response and overall survival (OS) in patients with metastatic hormone-sensitive prostate cancer (mHSPC) from the Phase III ARASENS trial","volume":"40","author":"Saad F","year":"2022","unstructured":"Saad F, Hussain MH, Tombal BF Association of prostate-specific antigen (PSA) response and overall survival (OS) in patients with metastatic hormone-sensitive prostate cancer (mHSPC) from the Phase III ARASENS trial. J. Clin. Oncol. 40, 5078 (2022).","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"e_1_3_9_27_2","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.eururo.2021.11.020","article-title":"Deep prostate-specific antigen response following addition of apalutamide to ongoing androgen deprivation therapy and long-term clinical benefit in SPARTAN","volume":"81","author":"Saad F","year":"2022","unstructured":"Saad F, Small EJ, Feng FY Deep prostate-specific antigen response following addition of apalutamide to ongoing androgen deprivation therapy and long-term clinical benefit in SPARTAN. Eur. Urol. 81(2), 184\u2013192 (2022).","journal-title":"Eur. Urol."},{"issue":"4","key":"e_1_3_9_28_2","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1200\/JCO.2017.75.3921","article-title":"Seven-month prostate-specific antigen is prognostic in metastatic hormone-sensitive prostate cancer treated with androgen deprivation with or without docetaxel","volume":"36","author":"Harshman LC","year":"2018","unstructured":"Harshman LC, Chen Y-H, Liu G Seven-month prostate-specific antigen is prognostic in metastatic hormone-sensitive prostate cancer treated with androgen deprivation with or without docetaxel. J. Clin. Oncol. 36(4), 376\u2013382 (2018).","journal-title":"J. Clin. Oncol."},{"issue":"15","key":"e_1_3_9_29_2","doi-asserted-by":"crossref","first-page":"2450","DOI":"10.1200\/JCO.2008.19.9810","article-title":"Prostate-specific antigen progression predicts overall survival in patients with metastatic prostate cancer: Data from Southwest Oncology Group Trials 9346 (Intergroup Study 0162) and 9916","volume":"27","author":"Hussain M","year":"2009","unstructured":"Hussain M, Goldman B, Tangen C Prostate-specific antigen progression predicts overall survival in patients with metastatic prostate cancer: Data from Southwest Oncology Group Trials 9346 (Intergroup Study 0162) and 9916. J. Clin. Oncol. 27(15), 2450\u20132456 (2009).","journal-title":"J. Clin. Oncol."},{"issue":"7","key":"e_1_3_9_30_2","doi-asserted-by":"crossref","first-page":"3437","DOI":"10.1007\/s12325-025-03207-6","article-title":"Overall survival with apalutamide versus enzalutamide in metastatic castration-sensitive prostate cancer","volume":"42","author":"Bilen MA","year":"2025","unstructured":"Bilen MA, Lowentritt B, Khilfeh I Overall survival with apalutamide versus enzalutamide in metastatic castration-sensitive prostate cancer. Adv. Ther. 42(7), 3437\u20133454 (2025).","journal-title":"Adv. Ther."},{"issue":"3","key":"e_1_3_9_31_2","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1111\/j.1464-410X.2010.09467.x","article-title":"Racial variation in the pattern and quality of care for prostate cancer in the USA: mind the gap","volume":"106","author":"Barocas DA","year":"2010","unstructured":"Barocas DA, Penson DF. Racial variation in the pattern and quality of care for prostate cancer in the USA: mind the gap. BJU Int. 106(3), 322\u2013328 (2010).","journal-title":"BJU Int."},{"issue":"2","key":"e_1_3_9_32_2","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1200\/JCO.23.00949","article-title":"Disparities with systemic therapies for Black men having advanced prostate cancer: where do we stand?","volume":"42","author":"Gong J","year":"2024","unstructured":"Gong J, Kim DM, De Hoedt AM Disparities with systemic therapies for Black men having advanced prostate cancer: where do we stand? J. Clin. Oncol. 42(2), 228\u2013236 (2024).","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"e_1_3_9_33_2","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1038\/s41391-018-0083-4","article-title":"Evaluation of the contribution of demographics, access to health care, treatment, and tumor characteristics to racial differences in survival of advanced prostate cancer","volume":"22","author":"Krimphove MJ","year":"2019","unstructured":"Krimphove MJ, Cole AP, Fletcher SA Evaluation of the contribution of demographics, access to health care, treatment, and tumor characteristics to racial differences in survival of advanced prostate cancer. Prostate Cancer Prostatic Dis. 22(1), 125\u2013136 (2019).","journal-title":"Prostate Cancer Prostatic Dis."},{"issue":"12","key":"e_1_3_9_34_2","doi-asserted-by":"crossref","first-page":"e2345906","DOI":"10.1001\/jamanetworkopen.2023.45906","article-title":"Racial and ethnic disparities in use of novel hormonal therapy agents in patients with prostate cancer","volume":"6","author":"Ma TM","year":"2023","unstructured":"Ma TM, Agarwal N, Mahal B Racial and ethnic disparities in use of novel hormonal therapy agents in patients with prostate cancer. JAMA Netw. Open 6(12), e2345906 (2023).","journal-title":"JAMA Netw. Open"}],"container-title":["Journal of Comparative Effectiveness Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/becarispublishing.com\/doi\/pdf\/10.57264\/cer-2025-0161","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T10:15:53Z","timestamp":1770286553000},"score":1,"resource":{"primary":{"URL":"https:\/\/becarispublishing.com\/doi\/10.57264\/cer-2025-0161"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":32,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["10.57264\/cer-2025-0161"],"URL":"https:\/\/doi.org\/10.57264\/cer-2025-0161","relation":{},"ISSN":["2042-6305","2042-6313"],"issn-type":[{"value":"2042-6305","type":"print"},{"value":"2042-6313","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2]]},"article-number":"e250161"}}